Savvy Advisors Inc. grew its stake in shares of Medtronic PLC (NYSE: MDT) by 85.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,777 shares of the medical technology company's stock after acquiring an additional 13,716

Medtronic (NYSE: MDT - Get Free Report) and Omeros (NASDAQ: OMER - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Volatility and Risk Medtronic has a beta of 0.75, suggesting

Medtronic (NYSE: MDT - Get Free Report) and MacroGenics (NASDAQ: MGNX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations. Profitability This table compares Medtronic and MacroGenics' net margins, return

Stratos Wealth Partners LTD. cut its stake in shares of Medtronic PLC (NYSE: MDT) by 9.1% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 74,371 shares of the medical technology company's stock after selling 7,442 shares during the period. Stratos Wealth Partners LTD.'s holdings

Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still evolving — and not always as...

Tilray Inc (NASDAQ:TLRY) earned a repeat ‘Buy’ rating from Jefferies analysts after what it described as a solid third quarter earnings report, pointing to...

Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter...

The forex market now turns over $9.6 trillion every single day. That figure, confirmed by the Bank for International Settlements in its 2025 Triennial...

Medtronic wins FDA's approval for Stealth AXiS in cranial & ENT, expanding its AI-driven surgical platform after spine clearance and boosting growth prospects.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology's 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electr.